login

Safety of and compliance with community-based ivermectin therapy

The LancetPublished 1 June 1990
Michel Pacqué, Beatriz Muñoz, Hugh R. Taylor, Zd Dukuly, Bruce M. Greene, A.T White
Citations62
SJR quartileQ1
SJR score12.11
SNIP22.72

TL;DR

The data show that community-based treatment with ivermectin is well accepted and effective in reducing microfilarial loads and is likely to provide the first realistic means of chemotherapy-based control of onchocerciasis on a mass scale.

Abstract

In a study of the safety, acceptability, and efficacy of ivermectin for community-based mass treatment of onchocerciasis, the drug was issued twice, one year apart, to the population of a rubber plantation (14,000 people) in Liberia, where over 80% of the adults have Onchocerca volvulus infection. The plantation microfilarial load in a sample of adults was reduced by 86% 6 months after initial treatment and by 78% after 1 year. Compliance was 97% with each round of treatment. After the initial treatment of 7699 people, 101 (1.3%) had moderate adverse reactions. After re-treatment only 37 (0.5%) people had moderate adverse reactions. No ivermectin-related death or severe adverse reactions occurred. The data show that community-based treatment with ivermectin is well accepted and effective in reducing microfilarial loads. Ivermectin is likely to provide the first realistic means of chemotherapy-based control of onchocerciasis on a mass scale.

Keywords

Immunology and MicrobiologyMedicineEnvironmental Science